Ann: Presentation at 2nd Annual Oligonucleotide for CNS Summit, page-3

How fascinating.

Its not your usual conference where biotechs promote their wares: INDs, clinical trial programs, platforms. Its more about tools or as the conference blurb says the critical insights pharma and biotech need to accelerate oligonucleotide therapeutic development in the CNS. So what are we doing there? If I might say so that's a good question.

It appears to me that there is growing international interest in a particular target in the CNS that - as far as I understand - is protected by an important patent in the field of oligonucleotides. Circulating white blood cells and in particular a target called CD49d. In a sense ATL1102 is going along for the ride but due to the patent it could be an incredible journey of drug discovery.